Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST) by Taylor, PC, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Mueller, M, Liau, KF, Haraoui, B

“…<strong>Objective</strong> Report results from PERSIST, a real-life, observational, prospective cohort study of CT-P13, an infliximab (IFX) biosimilar, for treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) who were biologic-naïve or switched from IFX reference product (IFX-RP; Remicade®). …”

Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports by Moore, R, Derry, S, McQuay, H

“…Methods: We examined company clinical trial reports of trials involving etoricoxib in four musculoskeletal conditions: osteoarthritis, rheumatoid arthritis, chronic low back pain and ankylosing spondylitis. Information was available from 18 randomized trials (10,143 patients) lasting 4 to 12 weeks (one 4 weeks, three 6 weeks, one 8 weeks and seven 12 weeks) and from three trials with a mean duration of about 80 weeks (34,695 patients). …”

TLR expression profiles are a function of disease status in rheumatoid arthritis and experimental arthritis by Clanchy, FIL, Borghese, F, Bystrom, J, Balog, A, Penn, H, Hull, DN, Wells, GMA, Kiriakidis, S, Taylor, PC, Sacre, SM, Williams, LM, Stone, TW, Mageed, RA, Williams, RO

“…Toll-like receptor (TLR) expression profiles were analysed in tissues with differing disease status in rheumatoid arthritis (RA), ankylosing spondylitis (AS), and in experimental arthritis. TLR gene expression was measured in whole blood and monocytes, before and after TNF blockade. …”

Genetic variants in ERAP1 and ERAP2 associated with immune-mediated diseases influence protein expression and the isoform profile by Hanson, A, Cuddihy, T, Haynes, K, Loo, D, Morton, C, Oppermann, U, Leo, P, Thomas, G, Lê Cao, K, Kenna, T, Brown, M

“…</p> <h4>Results</h4> <p>Polymorphisms associated with ankylosing spondylitis (AS) significantly influenced the transcript and protein expression of ERAP‐1 and ERAP‐2. …”

Non-conventional forms of HLA-B27 are expressed in spondyloarthritis joints and gut tissue by Rysnik, O, McHugh, K, van Duivenvoorde, L, van Tok, M, Guggino, G, Taurog, J, Kollnberger, S, Ciccia, F, Baeten, D, Bowness, P

“…Human leukocyte antigen (HLA)-B27 (B27) is the strongest genetic factor associated with development of Ankylosing Spondylitis and other spondyloarthropathies (SpA), yet the role it plays in disease pathogenesis remains unclear. …”

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force by Smolen, JS, Schöls, M, Braun, J, Dougados, M, FitzGerald, O, Gladman, DD, Kavanaugh, A, Landewé, R, Mease, P, Sieper, J, Stamm, T, Wit, MD, Aletaha, D, Baraliakos, X, Betteridge, N, Bosch, FVD, Coates, LC, Emery, P, Gensler, LS, Gossec, L, Helliwell, P, Jongkees, M, Kvien, TK, Inman, RD, McInnes, IB, Maccarone, M, Machado, PM, Molto, A, Ogdie, A, Poddubnyy, D, Ritchlin, C, Rudwaleit, M, Tanew, A, Thio, B, Veale, D, Vlam, KD, van der Heijde, D

“…As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. …”

Real-world safety data from patients with rheumatic diseases treated with CT-P13, an infliximab biosimilar: an interim analysis from an observational study by Taylor, P, Christensen, R, Moosavi, S, Selema, P, Guilatco, R, Fowler, H, Bombardier, C, Haraoui, B

“…PERSIST is an ongoing, observational cohort study evaluating CT-P13 as treatment for rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in a real-world setting.…”

Causal relationship between several autoimmune diseases and renal malignancies: A two-sample mendelian randomization study. by Puyu Liu, Jihang Luo, Lanlan Zhao, Qingqing Fu, Yao Chen, Chengfang Li, Jieyu Xu, Xiaorong Yang

“…<h4>Results</h4>Acute and subacute iridocylitis (P = 0.006, OR = 1.077), Ankylosing spondylitis (P = 0.002, OR = 1.051), and spondyloarthritis (P = 0.009, OR = 1.073) were positively associated with an increased risk of renal malignancy. …”
Get full text

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study by T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova

“…Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind period of the PATERA study.Objective. …”
Get full text

The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial by Elham Rajaei, Khaled Bavieh, Karim Mowla, Ali Ghorbani, Nooshin Movaffagh

“…Results There were no statistically significant differences in Visual Analogue Scale (VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) criteria and finger-to-floor (FTF) levels in the intervention and control groups. …”
Get full text

Quantile-dependent expressivity of serum C-reactive protein concentrations in family sets by Paul T. Williams

“…Conclusion Heritability of serum CRP concentration is quantile-specific, which may explain or contribute to the inflated CRP differences between CRP (rs1130864, rs1205, rs1800947, rs2794521, rs3091244), FGB (rs1800787), IL-6 (rs1800795, rs1800796), IL6R (rs8192284), TNF-α (rs1800629) and APOE genotypes following CABG surgery, stroke, TIA, curative esophagectomy, intensive periodontal therapy, or acute exercise; during acute coronary syndrome or Staphylococcus aureus bacteremia; or in patients with chronic rheumatoid arthritis, diabetes, peripheral arterial disease, ankylosing spondylitis, obesity or inflammatory bowel disease or who smoke.…”
Get full text

Interleukin-26 Has Synergistic Catabolic Effects with Palmitate in Human Articular Chondrocytes via the TLR4-ERK1/2-c-Jun Signaling Pathway by Yi-Ting Chen, Chih-Chien Wang, Chia-Pi Cheng, Feng-Cheng Liu, Chian-Her Lee, Herng-Sheng Lee, Yi-Jen Peng

“…Obesity is associated with disability of patients with rheumatoid arthritis and disease activity in those with ankylosing spondylitis. The saturated free fatty acid palmitate with IL-1β can synergistically induce catabolic effects in HACs. …”
Get full text

Cribriform carcinoma mimicking breast abscess – case report. Diagnostic and therapeutic management by Katarzyna Dobruch‑Sobczak, Katarzyna Roszkowska‑Purska, Eryk Chrapowicki

“…The case concerns a 71-year-old female patient treated for ankylosing spondylitis, with a positive family history of breast cancer. …”
Get full text

Epidemiology and Characteristics of Spondyloarthritis in the Predominantly Afro-Descendant Population of Martinique, a French Caribbean Island by Fabienne Louis-Sidney, Valentine Kahn, Benoit Suzon, Michel De Bandt, Christophe Deligny, Serge Arfi, Georges Jean-Baptiste

“…To our knowledge, there is no data on SpA in Martinique, a French region in the Caribbean with a predominantly Afro-descendant population and a high level of healthcare. (2) Methods: This was a retrospective study of all SpA patients treated at the Fort de France University Hospital between 1 January 1997 and 1 January 2008. (3) Results: In our cohort of 86 SpA patients, age at diagnosis was late (41 years old), ankylosing spondylitis (AS) was the most frequent sub-type (60.5%), inflammatory bowel disease was the most frequent extra articular feature (23.3%) and no one had personal familial history of the disease. …”
Get full text

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis by Rubén Burgos-Vargas, Adalberto Loyola-Sanchez, Sofia Ramiro, Arturo Reding-Bernal, Everardo Alvarez-Hernandez, Desirée van der Heijde, Janitzia Vázquez-Mellado

“…Secondary outcomes included the assessment of disease activity, tender entheses, spinal mobility, serum C-reactive protein (CRP), the Bath Ankylosing Spondylitis Disease Activity and Functional Index, and the Childhood Health Assessment Questionnaire (CHAQ). …”
Get full text

Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Reliability Study in Axial Spondyloarthritis by Megan O’Grady, Tom O’Dwyer, James Connolly, Joan Condell, Karla Muñoz Esquivel, Finbar D. O’Shea, Philip Gardiner, Fiona Wilson

“…Participant spinal mobility was assessed by conventional metrology (Bath Ankylosing Spondylitis Metrology Index, linear version—BASMI_Lin) and by a wireless IMU sensor-based system which measured lumbar flexion-extension, lateral flexion and rotation. …”
Get full text

Phenome-wide causal associations between osteoarthritis and other complex traits through the latent causal variable analysis by Lin Mei, Zhiming Zhang, Ruiqi Chen, Zhihong Li

“…Soft tissue and musculoskeletal disorders, such as hallux valgus, internal derangement of the knee, and spondylitis, were also identified to be causally related to osteoarthritis. …”
Get full text

Predicting Biologic Therapy Outcome of Patients With Spondyloarthritis: Joint Models for Longitudinal and Survival Analysis by Carolina Barata, Ana Maria Rodrigues, Helena Canhão, Susana Vinga, Alexandra M Carvalho

“…ResultsOur results show that being a male, starting biologic therapy at an older age, having a larger time interval between disease start and initiation of the first biologic drug, and being human leukocyte antigen (HLA)–B27 positive are indicators of a good prognosis for the biological drug survival; meanwhile, having disease onset or biologic therapy initiation occur in more recent years, a larger number of education years, and higher values of C-reactive protein or Bath Ankylosing Spondylitis Functional Index (BASFI) at baseline are all predictors of a greater risk of failure of the first biologic therapy. …”
Get full text

Case Report: Metagenomic Next-Generation Sequencing Confirmed a Case of Spine Infection with Brucella melitensis in Non-Endemic Area by Du J, Tao Y, Yang J, Cai J, Zhou H, Zhang R, Hu Y

“…The patient’s history as a shepherd and a positive Rose Bengal plate test (RBPT) further supported the diagnosis of brucella spondylitis. In order to alleviate pain and restore spinal function, the patient underwent posterior internal fixation of the thoracic spine. …”
Get full text

Impact of disease outcomes on the Assessment of SpondyloArthritis International Society Health Index (ASAS HI): a Bayesian network analysis of the DESIR cohort by Sofia Ramiro, Robert Landewé, Désirée van der Heijde, Maxime Dougados, Annelies Boonen, Jürgen Braun, Uta Kiltz, Imke Redeker

“…Disease outcomes comprised, among others, the Ankylosing Spondylitis (AS) Disease Activity Score (ASDAS) and the Bath AS Functional Index (BASFI).Results Data of 384 patients were analysed. …”
Get full text